Spots Global Cancer Trial Database for solid
Every month we try and update this database with for solid cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Feasibility Study of Genomic Sequencing to Find Potential Targets for Personalized Therapy | NCT01869218 | Hematologic Neo... | 18 Years - | University of Colorado, Denver | ||
| Pharmacokinetic, Safety and Tolerability Study of SPARC1028 | NCT01305512 | Solid Tumor in ... | SPARC1028 | 18 Years - | Sun Pharma Advanced Research Company Limited | |
| Pharmacokinetic and Safety Study of SPARC1023 Alone and in Carboplatin Combination | NCT01304303 | Solid Tumor in ... | SPARC1023 I SPARC1023 II | 18 Years - | Sun Pharma Advanced Research Company Limited | |
| 68Ga-FAPI-RGD PET/CT for Dual Integrin αvβ3 and FAP-targeted Imaging in Patients With Various Types of Cancer and Compared With 18F-FDG | NCT05543317 | Tumor, Solid Positron-Emissi... | 18F-FDG PET/CT,... | 18 Years - 90 Years | The First Affiliated Hospital of Xiamen University | |
| ImmunoPET Targeting Trophoblast Cell-surface Antigen 2 (Trop-2) in Solid Tumors | NCT06188468 | Tumor Solid Tumor Positron-Emissi... | standard-of-car... | 18 Years - 90 Years | The First Affiliated Hospital of Xiamen University | |
| First-in-Human Study of EOS100850 in Patients With Cancer | NCT03873883 | Solid Tumor, Ad... | EOS100850 Pembrolizumab Chemotherapy | 18 Years - | iTeos Therapeutics | |
| Safety Study to Evaluate CHR-2797 in Patients With Advanced Tumours | NCT00692354 | Advanced Solid ... | CHR-2797 (tosed... | 18 Years - | Chroma Therapeutics | |
| 68Ga-FAPI-RGD PET/CT for Dual Integrin αvβ3 and FAP-targeted Imaging in Patients With Various Types of Cancer and Compared With 18F-FDG | NCT05543317 | Tumor, Solid Positron-Emissi... | 18F-FDG PET/CT,... | 18 Years - 90 Years | The First Affiliated Hospital of Xiamen University | |
| Study To Assess Long Term Safety Of Pazopanib | NCT00387205 | Carcinoma, Rena... | Pazopanib | 18 Years - | Novartis | |
| First in Human Study of T3P-Y058-739 (T3P) | NCT05120596 | Advanced Solid ... | Pembrolizumab+T... T3P-Y058-739 (I... T3P-Y058-739 (I... | 18 Years - | T3 Pharmaceuticals AG | |
| Comaprison of 68Ga-FAP-2286 and 18F-FDG PET/CT in Patients With Various Types of Cancer | NCT05392205 | Tumor, Solid Positron-Emissi... | 18F-FDG | 18 Years - | The First Affiliated Hospital of Xiamen University | |
| First in Human Study of T3P-Y058-739 (T3P) | NCT05120596 | Advanced Solid ... | Pembrolizumab+T... T3P-Y058-739 (I... T3P-Y058-739 (I... | 18 Years - | T3 Pharmaceuticals AG | |
| Study of Safety and Efficacy of Glufosfamide in Combination With Gemcitabine in Cancer | NCT00102752 | Neoplasms Pancreatic Neop... | Glufosfamide Gemcitabine | 18 Years - | Threshold Pharmaceuticals | |
| Safety Study of Increasing Doses of Combretastatin in Combination With Bevacizumab (Avastin) in Patients With Advanced Solid Tumors | NCT00395434 | Tumors | Combretastatin ... Bevacizumab (Av... | 18 Years - | Mateon Therapeutics | |
| Safety and Tolerability Study of SNS-314 for Advanced Solid Tumors | NCT00519662 | Advanced Solid ... | SNS-314 | 18 Years - | Sunesis Pharmaceuticals | |
| Study To Assess Long Term Safety Of Pazopanib | NCT00387205 | Carcinoma, Rena... | Pazopanib | 18 Years - | Novartis | |
| Pharmacokinetic and Safety Study of SPARC1023 Alone and in Carboplatin Combination | NCT01304303 | Solid Tumor in ... | SPARC1023 I SPARC1023 II | 18 Years - | Sun Pharma Advanced Research Company Limited | |
| A Study of HLX06, a Humanized Monoclonal Antibody Targeting Human Vascular Endothelial Growth Factor Receptor-2 in Patients With Advanced Solid Tumors | NCT03494231 | Solid Tumor, Ad... | HLX06 | 18 Years - | Henlix, Inc |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
